Article
Rheumatology
Hao-Guang Li, Dan-Min Wang, Feng-Cai Shen, Shu-Xin Huang, Zhi-Duo Hou, Ling Lin, Zheng-Yu Xiao
Summary: Peripheral involvement is common in juvenile-onset non-radiographic axial spondyloarthritis, and risk factors associated with progression to juvenile-onset ankylosing spondylitis include inflammatory back pain, buttock pain, enthesitis, elevated baseline CRP levels, and sacroiliac joint-MRI positivity.
Article
Medicine, General & Internal
Atul Deodhar, Filip Van den Bosch, Denis Poddubnyy, Walter P. Maksymowych, Desiree van der Heijde, Tae-Hwan Kim, Mitsumasa Kishimoto, Ricardo Blanco, Yuanyuan Duan, Yihan Li, Aileen L. Pangan, Peter Wung, In-Ho Song
Summary: Upadacitinib demonstrates significant efficacy and safety in patients with non-radiographic axial spondyloarthritis.
Article
Rheumatology
Atul Deodhar, Paula Sliwinska-Stanczyk, Huji Xu, Xenofon Baraliakos, Lianne S. Gensler, Dona Fleishaker, Lisy Wang, Joseph Wu, Sujatha Menon, Cunshan Wang, Oluwaseyi Dina, Lara Fallon, Keith S. Kanik, Desiree van der Heijde
Summary: Tofacitinib demonstrated significantly greater efficacy compared to placebo in treating active ankylosing spondylitis in adults, with good safety profile and no new safety risks identified.
ANNALS OF THE RHEUMATIC DISEASES
(2021)
Article
Immunology
Zena Chen, Xuqi Zheng, Xinyu Wu, Jialing Wu, Xiaomin Li, Qiujing Wei, Xi Zhang, Linkai Fang, Ou Jin, Jieruo Gu
Summary: The study found that the gut microbiome was significantly restored in AS patients after adalimumab therapy, with a higher abundance of Comamonas in non-responders compared to responders, although no statistical difference was observed. These results suggest the potential of gut microbiome as biomarkers for therapeutic evaluation.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Rheumatology
Walter Reinisch, Wayne Hellstrom, Radboud J. E. M. Dolhain, Suresh Sikka, Rene Westhovens, Rajiv Mehta, Timothy Ritter, Ursula Seidler, Oleksandr Golovchenko, Vladimir Simanenkov, Olena Garmish, Slawomir Jeka, Radka Moravcova, Vijay Rajendran, Franck-Olivier Le Brun, Sarah Arterburn, Timothy R. Watkins, Robin Besuyen, Dirk Vanderschueren
Summary: The phase 2 MANTA and MANTA-RAy studies aimed to determine the impact of the oral Janus kinase 1 inhibitor filgotinib on semen parameters and sex hormones in men with inflammatory diseases. Results showed that once daily filgotinib 200 mg for 13 weeks had no measurable impact on semen parameters or sex hormones.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Desiree van der Heijde, Xenofon Baraliakos, Joachim Sieper, Atul Deodhar, Robert D. Inman, Hideto Kameda, Xiaofeng Zeng, Yunxia Sui, Xianwei Bu, Aileen L. Pangan, Peter Wung, In-Ho Song
Summary: This study evaluated the efficacy and safety of upadacitinib in patients with active ankylosing spondylitis who had an inadequate response to biological disease-modifying antirheumatic drugs. The results showed that upadacitinib was significantly more effective than placebo over a 14-week treatment period, and no new safety risks were identified.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Rheumatology
Desiree van der Heijde, Atul Deodhar, Walter P. Maksymowych, Joachim Sieper, Filip Van den Bosch, Tae-Hwan Kim, Mitsumasa Kishimoto, Andrew J. Ostor, Bernard Combe, Yunxia Sui, Yuanyuan Duan, Peter K. Wung, In-Ho Song
Summary: Upadacitinib 15 mg once daily demonstrated sustained and consistent efficacy in the long-term treatment of active ankylosing spondylitis. It effectively inhibited radiographic progression and no new safety concerns were identified in the clinical trial.
Article
Rheumatology
Jia Li, Zhixin Xue, Zhenbiao Wu, Liqi Bi, Huaxiang Liu, Lijun Wu, Shengyun Liu, Xiangyang Huang, Yong Wang, Yan Zhang, Wufang Qi, Lan He, Lie Dai, Lingyun Sun, Xiaomei Li, Zongwen Shuai, Yi Zhao, Yanyan Wang, Jian Xu, Hao Zhang, Hao Yu, Xiaoxiang Chen, Chunde Bao
Summary: This study aimed to evaluate the clinical equivalence of TQ-Z2301, a biosimilar of adalimumab, to the reference adalimumab in Chinese patients with active ankylosing spondylitis. The results showed that TQ-Z2301 was equivalent to adalimumab in terms of efficacy, safety, immunogenicity, and pharmacokinetic characteristics.
CLINICAL RHEUMATOLOGY
(2022)
Article
Rheumatology
Atul Deodhar, Ricardo Blanco, Eva Dokoupilova, Stephen Hall, Hideto Kameda, Alan J. Kivitz, Denis Poddubnyy, Marleen van de Sande, Anna S. Wiksten, Brian O. Porter, Hanno B. Richards, Sibylle Haemmerle, Juergen Braun
Summary: The study demonstrates that secukinumab 150 mg provides significant and sustained improvement in patients with active nonradiographic axial spondyloarthritis (SpA) through 52 weeks. The safety profile is consistent with previous reports.
ARTHRITIS & RHEUMATOLOGY
(2021)
Article
Rheumatology
James Cheng-Chung Wei, Tae-Hwan Kim, Mitsumasa Kishimoto, Naoki Ogusu, Haeyoun Jeong, Shigeto Kobayashi
Summary: Brodalumab demonstrated significant improvement in patients with active axSpA at week 16. The safety profile of brodalumab was consistent with previous reports from global/Japanese psoriasis studies.
ANNALS OF THE RHEUMATIC DISEASES
(2021)
Review
Rheumatology
Priyanka Iyer, Mark Hwang, Lauren Ridley, Michael M. Weisman
Summary: Increasing evidence suggests that mechanotransduction plays a pivotal role in the initiation and propagation of spondyloarthritis. This review examines the evidence and explores the unsolved question of how biomechanical forces contribute to the development and progression of ankylosing spondylitis.
Article
Rheumatology
Jinmei Su, Mengtao Li, Lan He, Dongbao Zhao, Weiguo Wan, Yi Liu, Jianhua Xu, Jian Xu, Huaxiang Liu, Lindi Jiang, Huaxiang Wu, Xiaoxia Zuo, Cibo Huang, Xiumei Liu, Fen Li, Zhiyi Zhang, Xiangyuan Liu, Lingli Dong, Tianwang Li, Haiying Chen, Jingyang Li, Dongyi He, Xin Lu, Anbin Huang, Yi Tao, Yanyan Wang, Zhuoli Zhang, Wei Wei, Xiaofeng Li, Xiaofeng Zeng
Summary: The study found that both HS016 and adalimumab rapidly improved symptoms within the first two weeks of treatment and HS016 may be an alternative cost-effective treatment option for Chinese AS patients, providing rapid relief and improving overall quality of life.
CLINICAL RHEUMATOLOGY
(2022)
Article
Parasitology
Xuegang Li, Nelson Siu Kei Lam, Li Yang, Anqi Liang, Xin Xin Long, Junli Guo, Shuping Zhong
Summary: This study investigated the impact of TNF-alpha inhibitor adalimumab on changes in Demodex density in patients with ankylosing spondylitis (AS). The findings revealed that Demodex density was positively correlated with age and C-reactive protein levels, and the number of Demodex mites could increase after adalimumab treatment in AS.
Article
Medicine, General & Internal
Arvind Chopra, Nagnath Khadke, Manjit Saluja, Toktam Kianifard, Anuradha Venugopalan, Mihir Gharia
Summary: This study aimed to observe the long-term relief after the short-term administration of an anti-TNF agent. The results showed that patients experienced early and significant improvement in various aspects after discontinuing injections. The unconventional method proved to be economically appealing and deserves further confirmation and acceptance, especially in resource-constrained contexts.
CUREUS JOURNAL OF MEDICAL SCIENCE
(2023)
Article
Rheumatology
Eric Peters, Richard C. Chou, Stephen J. Rozzo, Siu-Long Yao, Ferran Jose Garcia Fructuoso
Summary: This study evaluated the efficacy and safety of Tildrakizumab in patients with ankylosing spondylitis (AS). The results showed that Tildrakizumab treatment did not improve the ASAS20 response rate, but it was generally well tolerated.
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY
(2023)